The Ugly Side of Weight-Loss Drugs: Rotten Breath, Damaged Teeth, and Dry Mouth
Ozempic and Wegovy have been hailed as wonder drugs when it comes to weight loss. But as the drug has become more widely used, a number of unintended side-effects have become apparent—with the weight loss drug affecting the appearance of everything from your butt to your feet.
'Ozempic face' is another commonly reported consequences of using these popular weight loss drugs. This is a sunken or hollowed out appearance the face can take on in people taking weight loss drugs. It can also increase signs of ageing—including lines, wrinkles and sagging skin.
This happens because semaglutide (the active ingredient in both Ozempic and Wegovy) isn't localised to act just on the fat we want to lose. Instead, it targets all of our body's fat—including in the face.
But it isn't just the appearance of your face that semaglutide affects. These drugs may also affect the mouth and teeth, too. And these side-effects could potentially lead to lasting damage.
Dry mouth
Semaglutide effects the salivary glands in the mouth. It does this by reducing saliva production (hyposalivation), which can in turn lead to dry mouth (xerostomia). This means there isn't enough saliva to keep the mouth wet.
It isn't exactly clear why semaglutide has this effect on the salivary glands. But in animal studies of the drug, it appears the drug makes saliva stickier. This means there's less fluid to moisten the mouth, causing it to dry out.
GLP-1 receptor agonist drugs (such as semaglutide) can also reduce water intake by affecting areas in the brain responsible for thirst. Low fluid intake further reduces saliva production, and may even cause the saliva to become thick and frothy and the tongue to become sticky.
Bad breath
One other commonly reported unwanted effect by semaglutide users is bad breath (halitosis). When there's less saliva flowing through the mouth, this encourages bacteria that contribute to bad breath and the formation of cavities to thrive. These bacterial species include Streptococcus mutans and some strains of Lactobacillus.
Another species that has been shown to thrive in conditions where saliva is reduced is Porphyromonas gingivalis. This bacteria is a significant contributor to the production of volatile sulphur compounds, which cause the foul odours characteristic of halitosis.
Another factor that might explain why semaglutide causes bad breath is because less saliva being produced means the tongue isn't cleaned. This is the same reason why your 'morning breath' is so bad, because we naturally produce less saliva at night. This allows bacteria to grow and produce odours. Case report images show some people taking semaglutide have a 'furry'-like or coated appearance to their tongue. This indicates a build up of bacteria that contribute to bad breath.
Tooth damage
One of the major side-effects of Ozempic is vomiting. Semaglutide slows how quickly the stomach empties, delaying digestion which can lead to bloating, nausea, and vomiting.
Repeated vomiting can damage the teeth. This is because stomach acid, composed primarily of hydrochloric acid, erodes the enamel of the teeth. Where vomiting occurs over a prolonged period of months and years the more damage will occur. The back surface of the teeth (palatal surface) closest to the tongue are more likely to see damage–and this damage may not be obvious to the sufferer.
Vomiting also reduces the amount of fluid in the body. When combined with reduced saliva production, this puts the teeth at even greater risk of damage. This is because saliva helps neutralise the acid that causes dental damage.
Saliva also contributes to the dental pellicle—a thin, protective layer that the saliva forms on the surface of the teeth. It's thickest on the tongue-facing surface of the bottom row of teeth. In people who produce less saliva, the dental pellicle contains fewer mucins—a type of mucus which helps saliva stick to the teeth.
Reducing the risk of damage
If you're taking semaglutide, there are many things you can do to keep your mouth healthy.
Drinking water regularly during the day can help to keep the oral surfaces from drying out. This helps maintain your natural oral microbiome, which can reduce the risk of an overgrowth of the bacteria that cause bad breath and tooth damage.
Drinking plenty of water also enables the body to produce the saliva needed to prevent dry mouth, ideally the recommended daily amount of six to eight glasses. Chewing sugar-free gum is also a sensible option as it helps to encourage saliva production. Swallowing this saliva keeps the valuable fluid within the body. Gums containing eucalyptus may help to prevent halitosis, too.
There's some evidence that probiotics may help to alleviate bad breath, at least in the short term. Using a probiotic supplements or consuming probiotic-rich foods (such as yoghurt or kefir) may be a good idea.
Practising good basic oral hygiene, tooth brushing, reducing acidic foods and sugary drinks and using a mouthwash all help to protect your teeth as well.
Women are twice as likely to have side-effects when taking GLP-1 receptor agonists–including gastrointestinal symptoms such as vomiting. This may be due to the sex hormones oestrogen and progesterone, which can alter the gut's sensitivity. To avoid vomiting, try eating smaller meals since the stomach stays fuller for longer while taking semaglutide.
If you are sick, don't immediately brush your teeth as this will spread the stomach's acid over the surface of the teeth and increase the risk of damage. Instead, rinse your mouth out with water or mouthwash to reduce the strength of the acid and wait at least 30 minutes before brushing.
It isn't clear how long these side effects last, they'll likely disappear when the medication is stopped, but any damage to the teeth is permanent. Gastrointestinal side-effects can last a few weeks but usually resolve on their own unless a higher dose is taken.
Adam Taylor, Professor of Anatomy, Lancaster University. This article is republished from The Conversation under a Creative Commons license. Read the original article.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
U.S. Supreme Court orders review over religious challenge to New York abortion law
The U.S. Supreme Court on Monday ordered a lower court in New York to reevaluate whether some religious organizations should be excluded from a state mandate that requires employers to provide employee health care plans that include abortion coverage. The ruling from the high court said the case, Diocese of Albany v. Harris, should be sent back to New York courts to be reviewed again in light of an earlier unanimous Wisconsin case related to the Catholic Church groups being denied state tax exemptions. The justices pointed to the Wisconsin case because the New York case poses similar issues about states exempting religious employers and faith-based groups, The Associated Press reported. The New York case stems from a 2017 state mandate that requires health insurance plans provided by employers to include abortion coverage for situations that include rape and incest. The state mandate includes a religious exemption for institutions, but not for religious-affiliated groups. It was challenged by Catholic and Anglican nuns, Catholic dioceses, Christian churches and other faith organizations. They argued the religious exemption is so narrow that it violates the freedom of religion protected under the First Amendment. The most recent order from the Supreme Court is the second time the case has reached the justices after being litigated for years. After the state adopted the mandate in 2017, religious groups challenged it in state court. The appeals court upheld the regulation and the state refused to exempt religious organizations. In 2021, the religious groups appealed the state's ruling to the U.S. Supreme Court. Justices asked New York to reconsider based on its ruling in another case involving religion, Fulton v. Philadelphia. State courts found the Fulton decision was inapplicable to the situation, prompting the groups to bring it to the Supreme Court again. The religious liberty law firm Becket noted in a release that New York's exemption doesn't currently apply to some organizations, including the Carmelite Sisters for the Aged and Infirm and the Teresian Nursing Home because they 'serve the elderly and dying regardless of religious affiliation.' 'New York wants to browbeat nuns into paying for abortions for the great crime of serving all those in need,' Becket Vice President and senior counsel Eric Baxter said in a statement.' Following the Supreme Court's Monday order, the case is headed back to the New York Court of Appeals.
Yahoo
2 hours ago
- Yahoo
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice president and chief development officer, effective January 2026. Holly Kordasiewicz, Ph.D., currently senior vice president of neurology, will take over the role. Geary has been with Ionis since 1995 and played a pivotal role in bringing six medicines to regulatory approval, including the company's first independently commercialized drug, TRYNGOLZA. A biotechnologist pouring liquid into a test tube and analyzing its components in a lab. Dr. Kordasiewicz, who joined Ionis in 2011, brings over 20 years of experience in R&D, particularly in neurology. She leads the company's neurology program, covering treatments for conditions such as Alzheimer's disease, Angelman syndrome, and Alexander disease. Her work has also contributed to key partnered programs with Biogen, including the development of QALSODY® and IONIS-MAPTRx. As Dr. Geary transitions out of his role, he will continue as a strategic consultant through 2026 to ensure continuity. Ionis leadership praised both Geary's legacy and Kordasiewicz's appointment as a pivotal step in driving the company's commitment to developing transformational therapies for patients with serious diseases. Ionis Pharmaceuticals, Inc. is a U.S.-based commercial-stage biotech company specializing in RNA-targeted therapies. Its approved products include TRYNGOLZA for FCS, WAINUA, and TEGSEDI for ATTRv-PN, SPINRAZA for spinal muscular atrophy, QALSODY for ALS, and WAYLIVRA for rare lipid disorders. The company has a robust pipeline, including late-stage programs like Olezarsen (for hypertriglyceridemia), Donidalorsen (for hereditary angioedema), and Zilganerse (for Alexander disease), along with several mid-stage treatments for neurological and metabolic conditions. Ionis also collaborates with leading pharma firms, including Biogen, GSK, AstraZeneca, Novartis, Roche, and Metagenomi, expanding its reach in developing transformative RNA therapies. While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None.
Yahoo
2 hours ago
- Yahoo
Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the 10 biotech stocks screaming a buy. On June 17, the company moved to attract and retain top talent by granting inducement awards to 41 employees. Under the 2024 Inducement Plan, the company will award the employees non-qualified stock options of 187,664 shares and 89.582 restricted stock units designed to attract and retain talent. A pharmacist in a pharmacy preparing a prescription medication for a patient suffering from Fibromyalgia. The move to offer inducement awards is part of Acadia Pharmaceuticals' push to secure top-skilled professionals essential for its neuroscience projects. It expects the awards to ensure employees are incentivized to contribute to the long-term objectives expected to lead to sustained growth and innovation. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharma company dedicated to advancing treatments for central nervous system disorders and rare diseases. Its key products include NUPLAZID, approved for Parkinson's disease psychosis, and DAYBUE. While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
